H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Aeterna Zentaris (AEZS) today and set a price target of $3. The company’s shares closed yesterday at $2.38.
Ramakanth commented:
“We maintain our Buy rating of AEZS and adjust our 12-month price target to $3.00 per share. We derived our price target based on the average of two valuation methods: (1) price-sales multiple using 8x 2025 sales estimate discounted at 18%; and (2) price-earnings multiple using 25x 2025 earnings estimate also discounted at 18%.”
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.5% and a 34.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
Aeterna Zentaris has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.25 and a one-year low of $1.12. Currently, Aeterna Zentaris has an average volume of 420.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.
